Takeda’s Fruzaqla Gains the EC’s Approval for the treatment of Metastatic Colorectal Cancer
Shots:
- Following the CHMP’s positive opinion in Apr 2024, the EC has approved Fruzaqla (VEGFR-1, -2 & -3 inhibitor) alone in adults administered with prior standard therapies & progressed on/intolerant to trifluridine-tipiracil or regorafenib. It was approved in the US on Nov 8, 2023
- The approval was supported by a P-III (FRESCO-2) study assessing Fruzaqla + best supportive care (BSC) vs PBO + BSC in treatment-experienced mCRC adults
- The study reached all 1EPs & 2EPs, demonstrating consistent benefits & a favorable safety profile with treatment discontinuation due to AEs in 20% vs 21%. Results were published in The Lancet in Jun 2023
Ref: Takeda | Image: Takeda
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
